FY2023 Earnings Estimate for Hamilton Thorne Ltd. (CVE:HTL) Issued By Bloom Burton

Hamilton Thorne Ltd. (CVE:HTL – Get Rating) – Analysts at Bloom Burton dropped their FY2023 earnings per share (EPS) estimates for shares of Hamilton Thorne in a research note issued to investors on Tuesday, May 16th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings per share of $0.00 for the year, down from their previous forecast of $0.03. The consensus estimate for Hamilton Thorne’s current full-year earnings is $0.04 per share. Bloom Burton also issued estimates for Hamilton Thorne’s FY2024 earnings at $0.04 EPS.

Hamilton Thorne Price Performance

Hamilton Thorne stock opened at C$1.59 on Wednesday. The company has a debt-to-equity ratio of 31.78, a current ratio of 2.75 and a quick ratio of 2.25. The company has a market capitalization of C$230.28 million, a PE ratio of 53.00 and a beta of 0.53. Hamilton Thorne has a one year low of C$1.31 and a one year high of C$1.73. The business has a 50 day simple moving average of C$1.61 and a 200 day simple moving average of C$1.58.

About Hamilton Thorne

(Get Rating)

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers precision laser systems, imaging systems, and other equipment and consumables for the ART and developmental biology research markets under the Hamilton Thorne brand; test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services under the Embryotech brand.